Drugs / NHS7108
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07559175 | Apr 2026 → Jun 2027 expected | cystic fibrosis, exocrine pancreatic insufficiency | Aimmune Nestlé Health Science US R&D, LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NHS7108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07559175 ↗ |
| Modality | Protein / enzyme biologic | “It is a recombinant, modified version of a triacylglycerol lipase enzyme” NCT07559175 ↗ |
| Route | Oral | “Both NHS7108 and Zenpep® are oral capsules” NCT07559175 ↗ |